COVID Phenotyping Assay (CPA)

Our COVID Phenotyping Assay (CPA) is designed to evaluate critical immune cells and components, identifying areas of deficiency, overactivity, and dysfunction in the immune system. This comprehensive assay provides valuable insights into the immune response to SARS-CoV-2 and other infectious agents. Here are key aspects of our COVID Phenotyping Assay (CPA):

1. Evaluation of Immune Cells:
   • The CPA examines a wide range of immune cells to understand their roles and interactions in the context of SARS-CoV-2 infection.
   • Markers include: LAG-3, PD-1, Caspase 1 inhibitor, ICOS, HLA-DR, CD3, CD4, CD45RA, CD45RO, CD38, CD28, CD8, CD45, CXCR5, CCR5, CD39, CD127, CCR7, CD25, CD317, CD27, CD19, CD20.
2. Identifying Deficiencies:
   • The assay identifies specific areas of immune deficiency that may compromise the body’s ability to respond effectively to infections.
   • This information is critical for assessing patients’ risk for severe disease and tailoring preventive and therapeutic strategies.
3. Detecting Overactivity:
   • The CPA detects overactive immune responses, which can lead to excessive inflammation and tissue damage, a common complication in severe COVID-19 cases.
   • By identifying markers of immune overactivity, we can develop targeted interventions to modulate the immune response.
4. Assessing Immune Dysfunction:
   • The assay evaluates immune dysfunction, including impaired immune cell function and abnormal signaling pathways.
   • Understanding these dysfunctions helps in managing patients with long-term complications from COVID-19 and other viral infections.
5. Guiding Treatment Strategies:
   • The CPA provides detailed insights that inform the development of personalized treatment plans, enhancing the efficacy of interventions.
   • This assay helps clinicians make informed decisions about therapies that can modulate the immune system for better patient outcomes.
6. Immune Risk Assessment:
   • The CPA reveals high risk for severe disease from SARS-CoV-2 by identifying immune deficiencies as per CDC guidelines.
   • This risk assessment is vital for prioritizing patients for vaccination, antiviral treatments, and other preventive measures.

By utilizing the COVID Phenotyping Assay (CPA), we can provide a thorough evaluation of the immune response to SARS-CoV-2, helping to identify deficiencies, overactivity, and dysfunction. This detailed analysis is crucial for optimizing patient care, improving treatment outcomes, and managing the long-term effects of COVID-19.